BIT 0.00% 3.1¢ biotron limited

Important points in presentation

  1. 7,603 Posts.
    lightbulb Created with Sketch. 960
    CURE • 100% SVR12 (i.e. HCV cure)
    Market • Forecast to grow to over $19bn by 2016 Per annum
    Potential • Partnering still active • J&J partnered Achillion in US$1.1 bn deal in May ‘15; Merck bought Idenix for US$3.8 bn in June ‘14
    Lag • Significantly undervalued in comparison with other HCV companies
    Outcome • Continue commercialisation activities aimed at attracting partners
    Shareprice • BOOOM !!!!!
    GLTASH
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
3.1¢
Change
0.000(0.00%)
Mkt cap ! $27.97M
Open High Low Value Volume
3.2¢ 3.2¢ 3.1¢ $32.29K 1.025M

Buyers (Bids)

No. Vol. Price($)
1 6463 3.1¢
 

Sellers (Offers)

Price($) Vol. No.
3.2¢ 47000 2
View Market Depth
Last trade - 14.50pm 31/07/2024 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.